early type 2 diabetes
Conditions
Interventions
one dose of 100mg of sitagliptine
one dose of 90mg of nateglinide
Sponsors
Juntendo University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: the patients whose HbA1c level is more than 6.5% even after diet, excise. 1.the patients whose HbA1c are between 6.5 % and 8.0%. 2.the patients whose fasting glucose is less than 140 mg/dL. 3.the patients who have already started diet and exercise therapy for more than 3 months. 4.patients who are more than 20 year-old. 5.no restriction on sex 6.the patients who are able to read and understand the written informed consent.
Exclusion criteria
Exclusion criteria: 1) type 1 diabetes 2) patients who has been prescribed oral hypoglycemic agents 3) patients who have serious liver disease (AST and/or ALT are more than 100IU/L) 4) patients who have serious kidney disease (Serum Cr is more than 2.0mg/dL) 5) patients who have serious heart disease ( patients who have apparent heartfailure or myocardial infarction within 3 months) 6) patients who have serious pancreatic disease 7) patients with cancer 8) anemic patients (Hb is less than 11g/dL) 9) patients with thrombocytepenia (Platelet count is less than 100000/mm3) 10) patients with serious diabetic complications including progressed neutopathy and proliferative retinopathy 11) patietns with serious infection, inflammation, or injuary. pre- or post- operative state 12) patients who have inflammatory bowel disease, ulcer in bowel, ileus and high risk for ileus 13) patinets with chronic bowel diseases which have probability to induce malabsorption syndrome 14) patients who has the disease which is deteriorated with increase of gas in bowel 15) heavy alcohol drinker (patients who drink more than 480mL of Japanese Sake, 2L of beer, 180mL of whisky, 360mL of wine, or 360mL of Shochu per day) 16) patients who are pregnant, hope to be pregnant, or are in lactation period 17) patients who have viral infection (HBV,HCV) 18) patients who are not applicable to this study judged by the medical doctor.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To clarify which drug show more effective on glucose lowering after meal test between sitagliptin and nateglinide in the same patients? How each drug influences on insulin, glucagon or other glucose regulation hormones' secriton. | — |
Secondary
| Measure | Time frame |
|---|---|
| To clarify the effect of each drug on inflammatory cytekine level after the treatent To comfirm frequency of hypoglycemia after the treatment | — |
Countries
Japan
Outcome results
None listed